Clinical trials: Crohn Disease of Intestine
Crohn Disease (CD)
Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors.
- Trial name
- PREDICT-CD (NCT07316621)
- Where
- 10 sites in Italy, Netherlands and 4 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- GLSMED Learning Health S.A.
Crohn Disease
A Comparative Study of MRI, US and CE for Assessing Treatment Response in Known Crohn's Disease
The aim of this study is to evaluate non-invasive imaging techniques for assessing treatment response in known Crohn's disease. 1.
- Trial name
- NCT03435016
- Testing
- Diagnostic work-up
- Where
- Denmark
- Volunteers
- 62 people
- Sponsor
- Sygehus Lillebaelt
Crohn's Disease
MRE Predictors of Disease Relapse After Stopping Biologics
This study aims to investigate if MR Enterography (MRE) improves the ability to predict which Crohn's disease patients will relapse quickly (disease comes back) after stopping biologic medication.
- Trial name
- METEOR (NCT06124287)
- Testing
- MR Enterography (MRE)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Inflammatory Bowel Diseases, Crohn's Disease
Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
The purpose of this study is to assess the effect and safety of Tripterygium Glycosides in the treatment of Crohn's disease for induction remission and compare the therapeutic effect with patients who received mesalazine.
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Gastrointestinal Diseases, Digestive System Diseases
- Trial name
- NCT02044952
- Testing
- Mesalazine, Tripterygium glycosides
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhu Weiming
Crohn's Disease
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
To make adalimumab available to subjects suffering from moderately to severely active Crohn's Disease (CD) and to expand the safety information on adalimumab.
- Trial name
- ACCESS (NCT00427921)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abbott
Irritable Bowel Syndrome, Cyclical Vomiting Syndrome
Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.
The structural/RSN study involves Structural and Resting State Neuroimaging. The purpose of Structural Neuroimaging is to use MRI technology to identify cortical and white matter morphometric differences between patients with…
- Conditions
- Irritable Bowel Syndrome, Cyclical Vomiting Syndrome, Ulcerative Colitis, Vulvodynia
- Trial name
- MMI (NCT01517516)
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Crohn Disease
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease.
- Trial name
- NCT04978493
- Testing
- BI 706321, Ustekinumab
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease.
- Trial name
- NCT01155362
- Testing
- Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celularity Incorporated
Crohn's Disease
A Study of E6011 in Participants With Active Crohn's Disease
The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.
- Trial name
- NCT03733314
- Testing
- E6011
- Where
- 46 sites in Czechia, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- EA Pharma Co., Ltd.
Anal Fistula, Crohn's Disease
Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft
Healing anal fistulas in Crohn's patients with an anal fistula plug.
- Trial name
- SurgiSIS AFP (NCT00610207)
- Testing
- Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Cook Group Incorporated
Ulcerative Colitis, Crohn's Disease
Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease
The purpose of the study is to develop a validated French version of the IBDQ in a cohort of patients suffering from Inflammatory bowel diseases, namely Crohn's disease and Ulcerative Colitis.
- Trial name
- F-IBDQ (NCT01891214)
- Testing
- Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Rennes University Hospital
Inflammatory Bowel Diseases, Crohn Disease
Study of Dietary Composition in Crohn's Disease
Patients with inflammatory bowel disease (IBD) often have narrowed microbial diversity and altered composition and function of the gut microbiome.
- Trial name
- CD (NCT04431700)
- Testing
- Anti-inflammatory diet, Regular diet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, Los Angeles
Crohn's Disease
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
This study employs a multicenter, randomized, double-blind, placebo-controlled, parallel-group, continuous treatment design to evaluate the efficacy, safety, PPK characteristics, and PD effects of H021 Enteric-coated Tablets…
- Trial name
- NCT07677514
- Testing
- H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group
- Where
- 24 sites in United States, China
- Volunteers
- 156 people
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Crohn's Disease
Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease
This clinical study is designed to evaluate the effect of Mediterranean diet as an add-on therapy for induction of remission in adult patients with active Crohn's disease and to evaluate its effects on clinical, inflammatory and…
- Trial name
- NCT02825316
- Testing
- Mediterranean diet, Low residue diet
- Volunteers
- 100 people
- Sponsor
- michal roll
Exacerbation of Ulcerative Colitis, Ulcerative Colitis, Active Severe
Manipulating the Microbiome in IBD by Antibiotics and FMT
the etiology of Inflammatory Bowel Diseases (IBD) is closely associated with the gut microbiome. The results of previous studies on the effectiveness of antibiotics and fecal macrobiota transplantation (FMT) are contradicting.
- Conditions
- Exacerbation of Ulcerative Colitis, Ulcerative Colitis, Active Severe, Crohn's Colitis
- Trial name
- FMT (NCT02033408)
- Testing
- AB (antibiotics), CS (corticosteroids) Only
- Where
- 12 sites in Canada, Finland and 4 more
- Volunteers
- 28 people
- Sponsor
- Shaare Zedek Medical Center
Ulcerative Colitis, Crohn Disease
Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease
The gut microbiota is determined to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body's metabolism.
- Conditions
- Ulcerative Colitis, Crohn Disease, Constipation (Excl Faecal Impaction)
- Trial name
- NCT02575040
- Testing
- Fecal microbiota transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Inflammatory Bowel Diseases, Ulcerative Colitis
Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease
Specific Aim 1: Characterize the effects of vitamin D treatment on expression of α4β7 on B cells in patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT04828031
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Crohn's Disease
Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders
This project aims to assess safety and efficacy of allogeneic Mesenchymal stem Cell (MSC) in Crohn's disease refractory or intolerant to conventional therapies.
- Trial name
- NCT01540292
- Testing
- Mesenchymal Stem Cells (MSC)
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University of Liege
Crohn's Disease
A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).
- Trial name
- HarbOR (NCT02976129)
- Testing
- V565
- Where
- 94 sites in United States, Austria and 11 more
- Volunteers
- 125 people
- Sponsor
- VHsquared Ltd.
Intestinal Diseases, Ulcerative Colitis
Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease
Bioactive compounds from mango are bioavailable and their anti-inflammatory efficacy has been demonstrated in animals and humans.
- Conditions
- Intestinal Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT02227602
- Testing
- Mango polyphenolics
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Texas A&M University